Portfolio Review

Reevaluating shelved programs to bring forward new medicines

>80% of clinical stage drug candidates never achieve market approval.

However, these shelved programs can still have unexploited clinical and commercial potential when they accurately target the sub-population of patients that is most likely to respond to a drug for that mechanism using novel insights from our Portfolio Review.

Identify secondary indications

Revive stalled programs

Out-license shelved assets

Maximize ROI from R&D

Identify secondary indications

Revive stalled programs

Out-license shelved assets

Maximize ROI from R&D

Out-licensing opportunities

We identify multiple secondary indication opportunities with detailed supporting evidence packages covering MoA, genetic evidence, prevalence, druggability, modality and all supporting literature. This creates valuable new out-licensing propositions that combine primary and secondary indication data packages and regulatory submissions.

Drug program revival

Novel IP in the form of our mechanism-based patient stratification biomarkers allow biopharma companies to revive stalled programs. These biomarkers identify and select patients who are strong responders to the drug candidate for inclusion in clinical trials - derisking clinical development and accelerating approvals.

Patient Stratification Biomarkers

Our mechanism-based patient stratification biomarkers (PSBs) are unique, patentable IP that capture mechanistic insights into the mapping of causative disease biology to patient subgroups.

These disease insights go far beyond traditional genetic analysis or knowledge graph approaches and enable PrecisionLife to accurately evaluate a target’s secondary indication opportunities across multiple diseases and therapeutic areas.